Telaprevir: Additional Phase III data

A subgroup analysis of the double-blind, placebo-controlled, international Phase III ADVANCE trial in about 1,095 treatment-naïve patients with HCV genotype 1 infection showed that 8- and 12-week regimens of telaprevir plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) produced SVR rates of 58% and 62%, respectively, vs. 25% for SOC alone in African American patients (n=94); 66% and 74%, respectively, vs. 39% for SOC alone in Hispanic patients (n=117); and 53% and 62%, respectively, vs. 33% for SOC alone in patients with advanced liver fibrosis or cirrhosis (n=231). Data were presented at the American Association for the Study of Liver Diseases meeting in Boston. ...